ORHub, Inc. Acquires PUR Biologics, LLC

InVita Healthcare Technologies / The Riverside Company Acquire BloodHub

October 6, 2022

Cloud & SaaS

InVita Healthcare Technologies, a portfolio company of The Riverside Company, has acquired BloodHub and folded it into InVita's Blood Management Division. Riverside made the investment as an add-on to its InVita platform to expand InVita's blood- and biologics-focused supply chain and laboratory software capabilities across North America.

EmergentMedTech Merges with TRU Biologix

January 22, 2025

Biotechnology

EmergentMedTech announced a merger with TRU Biologix to integrate TRU Biologix's Wharton's Jelly–derived cell and tissue biologics into EmergentMedTech's regenerative medicine and aesthetics product portfolio. The deal expands EmergentMedTech's capabilities alongside its role as the exclusive U.S. distributor of NeoGen PSR, enabling delivery of advanced biologics to hundreds of clinics and clinician partners.

Young Innovations Acquires PuraGraft

November 11, 2019

Dental

Young Innovations, a portfolio company of The Jordan Company, has acquired PuraGraft, LLC, a Kingwood, Texas-based supplier of biomaterial solutions for bone and tissue regeneration and dental surgical supplies. The acquisition will expand Young Innovations' specialty dental product portfolio and support national distribution of PuraGraft's regenerative products, pharmaceuticals and related supplies.

Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B

December 6, 2021

Biotechnology

Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Junction Energy Capital and Ara Partners Invest in PURAGLOBE (Puralube, Inc.)

August 8, 2018

Energy

Houston-based private equity firms Junction Energy Capital and Ara Partners Group announced a joint investment in PURAGLOBE (Puralube, Inc.), a technology-driven base oil producer that uses recycled oil feedstock. Allied Resource Corporation, the founding shareholder, will retain a substantial stake alongside the new investors as PURAGLOBE expands operations in Germany and the United States.